<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44529">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02526602</url>
  </required_header>
  <id_info>
    <org_study_id>R15043</org_study_id>
    <nct_id>NCT02526602</nct_id>
  </id_info>
  <brief_title>Preservation of Endopelvic Fascia: Effects on Postoperative Incontinence and Impotence. Randomized Clinical Trial.</brief_title>
  <official_title>Preservation of Endopelvic Fascia During Radical Prostatectomy: Effects on Postoperative Incontinence and Impotence. Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urinary incontinence and impotence are typical disturbances after radical prostatectomy.
      Although, several surgical methods are developed to decrease these disturbances, 8% and 50%
      of the patients suffer from permanent urinary incontinence and impotence, respectively.

      Previously two studies have shown that endopelvic fascia preservation may decrease
      postoperative incontinence and impotence rates. Unfortunately these studies are
      retrospective decreasing their reliability.

      The present study is prospective and randomized clinical trial. The investigators are going
      to randomize 180 patient to preservation and opening the endopelvic fascia groups.
      Functional and oncological results are followed up to 1 year after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      180 patients going to radical prostatectomy as treatment of prostate cancer will be
      randomized 1:1 to two study arms: In the other arm endopelvic fascia are preserved during
      the operation, in the other arm the fascia are opened.

      After the operation urinary continence and erection function are compared between the study
      arms. Additionally the investigators will study oncological outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary incontinence</measure>
    <time_frame>1 year</time_frame>
    <description>EPIC-26 questionnaire preoperatively and 3 and 12 months after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Erectile function</measure>
    <time_frame>1 year</time_frame>
    <description>EPIC-26 questionnaire preoperatively and 3 and 12 months after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oncologic results: positive surgical margin rate</measure>
    <time_frame>1 year</time_frame>
    <description>Positive surgical margin rate as reported in pathological analysis of the removed prostate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>1 year</time_frame>
    <description>Clavien-Dindo classification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <condition>Urinary Incontinence</condition>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Preservation (endopelvic fascia)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are preserved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Opening (endopelvic fascia)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are opened.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Preservation (endopelvic fascia)</intervention_name>
    <description>Robotic assisted radical prostatectomy with preserving of endopelvic fascia</description>
    <arm_group_label>Preservation (endopelvic fascia)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Opening (endopelvic fascia)</intervention_name>
    <description>Robotic assisted radical prostatectomy with opening of endopelvic fascia</description>
    <arm_group_label>Opening (endopelvic fascia)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Localized prostate cancer

          -  Planned nerve-sparing robotic radical prostatectomy

          -  Gleason score 7 or less

        Exclusion Criteria:

          -  Previous prostate surgery (TURP, TUIP, laser...)

          -  Planned lymphadenectomy

          -  T3 cancer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jarno Riikonen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jarno Riikonen, MD</last_name>
    <email>jarno.riikonen@tays.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jarno Riikonen, MD</last_name>
      <email>jarno.riikonen@tays.fi</email>
    </contact>
    <contact_backup>
      <last_name>Teemu Murtola, MD</last_name>
      <email>teemu.murtola@uta.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>November 17, 2016</lastchanged_date>
  <firstreceived_date>August 10, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
